Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19.
Nat Biomed Eng
; 4(12): 1180-1187, 2020 12.
Article
in English
| MEDLINE | ID: covidwho-780007
ABSTRACT
Sensitive assays are essential for the accurate identification of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report a multiplexed assay for the fluorescence-based detection of seroconversion in infected individuals from less than 1 µl of blood, and as early as the day of the first positive nucleic acid test after symptom onset. The assay uses dye-encoded antigen-coated beads to quantify the levels of immunoglobulin G (IgG), IgM and IgA antibodies against four SARS-CoV-2 antigens. A logistic regression model trained using samples collected during the pandemic and samples collected from healthy individuals and patients with respiratory infections before the first outbreak of coronavirus disease 2019 (COVID-19) was 99% accurate in the detection of seroconversion in a blinded validation cohort of samples collected before the pandemic and from patients with COVID-19 five or more days after a positive nasopharyngeal test by PCR with reverse transcription. The high-throughput serological profiling of patients with COVID-19 allows for the interrogation of interactions between antibody isotypes and viral proteins, and should help us to understand the heterogeneity of clinical presentations.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunoassay
/
Seroconversion
/
COVID-19
Type of study:
Cohort study
/
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Aged
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Nat Biomed Eng
Year:
2020
Document Type:
Article
Affiliation country:
S41551-020-00611-x
Similar
MEDLINE
...
LILACS
LIS